Treatment of Oral Cavity Squamous Cell Carcinoma with High-Risk Features When Cisplatin Is Contraindicated

Clinical Scenario

This protocol applies to patients with oral cavity squamous cell carcinoma (SCC) who present with high-risk pathologic features after surgery — specifically, pathologic extranodal extension and/or positive surgical margins — and who are ineligible to receive cisplatin-based concurrent chemoradiation.

Cisplatin Ineligibility Criteria

Absolute contraindications to cisplatin in this setting include:

• ECOG performance status 3 or 4
• Renal dysfunction (creatinine clearance below 50 mL/min)
• Grade 2 or higher organ dysfunction, including deafness, tinnitus, or neurologic dysfunction
• Hypersensitivity to platinum compounds
• Pregnancy or lactation
• HIV/AIDS with CD4 count below 200/mL

When any of these criteria are present, an alternative concurrent systemic approach combined with postoperative radiation is warranted.

Treatment Approach

For cisplatin-ineligible patients with these high-risk pathologic features, evidence supports the use of a specific concurrent systemic agent alongside postoperative radiation therapy as the best-evidence option. Several alternative concurrent or radiation-modification strategies also exist for patients who cannot receive the preferred agent.

The complete regimen selection — including the preferred agent, alternatives, and clinical decision guidance — is available in the full structured protocol.